<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354042</url>
  </required_header>
  <id_info>
    <org_study_id>B2A100517</org_study_id>
    <nct_id>NCT00354042</nct_id>
  </id_info>
  <brief_title>Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is designed to look at the safety aspects and effects of repeat inhaled doses of
      GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive
      Pulmonary Disease(COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Tolerability including blood test results, effects on the heart, pulse rate and blood pressure, and any side effects.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on the lungs at 12 and 24 hours Effects on the heart, blood pressure and heart rate at 8 hours Effects on blood tests over 4 hours and 8 hours Reduction of rescue medication.</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW597901X</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects with mild to moderate stable asthma but no other lung problems.

          -  Male subjects or female subjects who are not able to get pregnant (e.g.
             post-menopausal or surgically sterile).

          -  Non-Smokers.

          -  Subjects who show a measurable improvement in the function of their lungs after a
             single dose of salbutamol.

        Exclusion criteria:

          -  Any significant illness.

          -  Subjects with heart problems.

          -  Subjects who have a cold or chest infection 2-4 weeks prior to the study or have
             life-threatening asthma.

          -  Subjects who take medication for their asthma, or other conditions, not compatible
             with this study.

          -  Subjects who are over sensitive to salbutamol or to ipratropium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD, MSc, FPPM</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>GW597901X</keyword>
  <keyword>Asthma</keyword>
  <keyword>Crossover</keyword>
  <keyword>dose ascending</keyword>
  <keyword>repeat dose</keyword>
  <keyword>inhaled</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

